Sawyer Jason David 4

What Happened
Jason D. Sawyer, a director of Lixte Biotechnology Holdings, received 40,000 restricted share units (RSUs) reported as an acquisition on July 1, 2026 at $0.00 per share. The filing states these RSUs vested upon satisfaction of the applicable performance conditions. The reported transaction is an equity award (compensation), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-01; Form 4 filed: 2026-07-02 (timely within the normal reporting window).
• Award: 40,000 RSUs granted/vested; reported acquisition price: $0.00.
• Shares owned following transaction: filing reports a total that includes the 40,000 newly awarded RSUs plus 25,000 previously awarded RSUs (all vested) — total shown = 65,000 RSUs/shares.
• Footnotes: F1 explains each RSU represents a contingent right to one share and vested after meeting performance conditions; F2 clarifies the 65,000 total includes the 25,000 RSUs previously awarded.
• Transaction code: A = Award/Grant (compensation); no sale or cash proceeds reported.

Context
RSUs are a form of equity compensation that convert to shares when vesting conditions are met; this transaction reflects compensation tied to performance/service rather than an insider buy or sell. Because the RSUs vested, the reporting person’s beneficial ownership increased, but this is not the same as an open-market purchase and does not by itself signal a trading intent.